Balaji Amines reported a solid performance for the quarter ended March 31, 2026. The company achieved consolidated revenue of INR 403 crores, marking a 12% year-on-year growth. Consolidated EBITDA rose to INR 102 crores with margins improving to 25%. Despite external challenges and brief production impacts in March, the company maintains a positive outlook, driven by its integrated manufacturing model and ongoing strategic expansion projects in high-value specialty chemicals.
Financial Highlights
For the fourth quarter of the financial year 2026, Balaji Amines demonstrated robust financial resilience. The company reported a total revenue of INR 403 crores, compared to INR 361 crores in the same quarter last year. Profit after-tax reached INR 65 crores, significantly higher than the INR 40 crores reported in Q4 FY25. The company’s EBITDA margin also saw a healthy expansion to 25%, supported by operational efficiencies, prudent inventory planning, and favorable product mix.
Strategic Growth and Project Updates
Balaji Amines continues to invest in long-term value creation. The Dimethyl Ether (DME) plant at Unit 4 is nearing completion and is expected to be commissioned in the first quarter of FY27. Additionally, the company is executing significant expansions in its specialty chemicals division, with a total investment phase of approximately INR 750 crores. These projects include new capacities for products such as Hydrogen Cyanide, Sodium Cyanide, and EDTA, which are vital for import substitution.
Future Outlook
Management remains optimistic about growth, guiding for a 10% to 15% volume growth for the consolidated business in the current financial year. The focus remains on strengthening the core amines and derivatives business, while scaling up production of electronic-grade chemicals. Despite global geopolitical tensions impacting raw material prices, the company expects to benefit from its diversified portfolio and the upcoming commissioning of new plants, aiming to reach INR 3,000 crores in total revenue by 2028.
Source: BSE
